SCHEMBL23958135

SCHEMBL23958135

O=c1c2ccccc2nc(Nc2ccc3ncoc3c2)n1-c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PRKD1 Q15139 2/20 0.49
TGFBR1 P36897 1/20 0.48
RAB9A P51151 3/20 0.46
NPC1 O15118 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
USP2 O75604 1/20 0.43
MAPT P10636 2/20 0.43
ALDH1A1 P00352 5/20 0.42
POLB P06746 3/20 0.42
KDM4E B2RXH2 3/20 0.42
MEN1 O00255 1/20 0.42
GAA P10253 1/20 0.42
KMT2A Q03164 1/20 0.42
LMNA P02545 1/20 0.39
NPY1R P25929 1/20 0.39
NPY2R P49146 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PDE7A Q13946 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23931384 0.91 PRKD1 (0.49) PRKD1TGFBR1RAB9ANPC1SMN1; SMN2
SCHEMBL30103271 0.91 PRKD1 (0.49) PRKD1TGFBR1RAB9ANPC1SMN1; SMN2
SCHEMBL24110866 0.80 USP2 (0.43) RAB9ANPC1USP2MAPTALDH1A1
SCHEMBL24111024 0.78 USP2 (0.43) RAB9ANPC1USP2MAPTALDH1A1
SCHEMBL23958140 0.78 RAB9A (0.43) RAB9ANPC1USP2MAPTALDH1A1
SCHEMBL30103292 0.77 TGFBR1 (0.51) TGFBR1RAB9AUSP2MAPTALDH1A1
SCHEMBL23931430 0.77 TGFBR1 (0.51) TGFBR1RAB9AUSP2MAPTALDH1A1
SCHEMBL24110951 0.74 USP2 (0.44) RAB9ANPC1USP2MAPTALDH1A1
SCHEMBL24090010 0.74 USP2 (0.52) RAB9ANPC1USP2MAPTALDH1A1
SCHEMBL24090012 0.74 TOP2A (0.60) RAB9ANPC1USP2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210387967-A1 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-12-16 US disclosed
WO-2021215537-A1 2-HETEROARYLAMINOQUINAZOLINONE DERIVATIVE 大日本住友製薬株式会社 (JP) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210387967-A1 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE CRKL, CLIC4, CLIC1 PRKD1 2931/4885TGFBR1 969/4885RAB9A 2222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.